| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11260053 | MIRUM | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
May, 2031
(7 years from now) | |
| US11376251 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(9 years from now) | |
| US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(16 years from now) | |
| US11497745 | MIRUM | NA |
Feb, 2040
(16 years from now) | |
Livmarli is owned by Mirum.
Livmarli contains Maralixibat Chloride.
Livmarli has a total of 4 drug patents out of which 0 drug patents have expired.
Livmarli was authorised for market use on 29 September, 2021.
Livmarli is available in solution;oral dosage forms.
Livmarli can be used as treatment of cholestatic pruritus in patients with alagille syndrome (algs).
Drug patent challenges can be filed against Livmarli from 2025-09-29.
The generics of Livmarli are possible to be released after 12 February, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 29, 2026 |
| Orphan Drug Exclusivity (ODE) | Sep 29, 2028 |
| New Patient Population (NPP) | Mar 13, 2026 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 2025-09-29
Market Authorisation Date: 29 September, 2021
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)
Dosage: SOLUTION;ORAL
LIVMARLI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic